Dr. Frank is the Director of the Clinical-Therapeutics Program of the Penn Center for AIDS Research, and he directs Pennís clinical trial unit of the HIV Vaccine Trials Network. His main areas of research include: i) mechanisms underlying immune activation and immunopathogenesis of HIV infection, ii) HIV vaccine and effectiveness of vaccination in HIV infected individuals, iii) strategies for HIV prevention, and iv) development of strategies to enhance update of HPV vaccination.
Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, Kovacs CM, Rodriguez B, Sieg SF, Teixeira-Johnson L, Gudonis D, Goepfert PA, Lederman MM, Frank I, Makedonas G, Kaul R, Walker BD, Betts MR. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathogens 27;6(5):e1000917, 2010.
Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A, Kenney T, Wagner W, Maffei K, Sullivan K. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 24:2187-92, 2010.
Gordon SN, Cervasi B, Odorizzi P, Silverman R, Aberra F, Ginsburg G, Estes JD, Paiardini M, Frank I, Silvestri G. Disruption of intestinal CD4+ T cell homeostasis is a key marker of systemic CD4+ T cell activation in HIV-infected individuals. Journal of Immunology 185:5169-79, 2010.
Fitzgerald DW, Janes H, Robertson M, Coombs R, Frank I, Gilbert P, Loufty M, Mehrotra D, Duerr A; for the Step Study Protocol Team. An Ad5-Vectored HIV-1 Vaccine Elicits Cell-mediated Immunity but does not Affect Disease Progression in HIV-1-infected Male Subjects: Results From a Randomized Placebo-Controlled Trial (The Step Study). Journal of Infectious Diseases 203:765-772, 2011.
Ian Frank, M.D.
502 Johnson Pavilion
36th St. and Hamilton Walk
University of Pennsylvania
Philadelphia, PA 19104-6073
Medical School: Dartmouth University
ID Training: University of Pennsylvania
Academic Rank: Professor of Medicine